• Explore /
  • Poster
  • / Preliminary results of a phase Ib/II combination study of RC48-ADC, a novel humanized anti-HER2 antibody-drug conjugate (ADC) with toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with locally advanced or metastatic urothelial carcinoma.

Preliminary results of a phase Ib/II combination study of RC48-ADC, a novel humanized anti-HER2 antibody-drug conjugate (ADC) with toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with locally advanced or metastatic urothelial carcinoma.

Abstract Poster

Authors

Xinan Sheng

Xinan Sheng

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Beijing Cancer Hospital, Beijing, China

Xinan Sheng , Li Zhou , Zhisong He , Hongqian Guo , Xieqiao Yan , Siming Li , Huayan Xu , Juan Li , Zhihong Chi , Lu Si , Chuanliang Cui , Lili Mao , BIN LIAN , Bixia Tang , Xuan Wang , Xue Bai , Jun Guo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Urothelial Cancer - Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT04264936

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 4518)

DOI

10.1200/JCO.2022.40.16_suppl.4518

Abstract #

4518

Poster Bd #

10

Abstract Disclosures

Similar Posters

First Author: Xinan Sheng

First Author: Li Zhou

First Author: Li Zhou

First Author: Matt D. Galsky